6F6R

Crystal structure of human Caspase-1 with N-{3-[1-((S)-2-Hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl}-4-(quinoxalin-2-ylamino)-benzamide

6F6R の概要

• エントリーDOI: 10.2210/pdb6f6r/pdb
• 分子名称: Caspase-1, (3~{S})-3-[[(2~{R})-2-[3-methyl-2,6-bis(oxidanylidene)-5-[[4-(quinoxalin-2-ylamino)phenyl]carbonylamino]pyrimidin-1-yl]propanoyl]amino]-4-oxidanyl-butanoic acid, SULFATE ION, ... (5 entities in total)
• 機能のキーワード: caspase-1, nanomolar inhibitor, inflammatory diseases, sp3 hybridization, hydrolase
• 由来する生物種: Homo sapiens (Human); 詳細
• 細胞内の位置: Cytoplasm: P29466 P29466
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 31029.42

構造登録者

Fournier, J.F.,Clary, L.,Chambon, S.,Dumais, L.,Harris, C.S.,Millois-Barbuis, C.,Pierre, R.,Talano, S.,Thoreau, E.,Aubert, J.,Aurelly, M.,Bouix-Peter, C.,Brethon, A.,Chantalat, L.,Christin, O.,Comino, C.,El-Bazbouz, G.,Ghilini, A.L.,Isabet, T.,Lardy, C.,Luzy, A.P.,Mathieu, C.,Mebrouk, K.,Orfila, D.,Pascau, J.,Reverse, K.,Roche, D.,Rodeschini, V.,Hennequin, L.F. (登録日: 2017-12-06, 公開日: 2018-05-02, 最終更新日: 2024-11-06)

主引用文献

Fournier, J.F.,Clary, L.,Chambon, S.,Dumais, L.,Harris, C.S.,Millois, C.,Pierre, R.,Talano, S.,Thoreau, E.,Aubert, J.,Aurelly, M.,Bouix-Peter, C.,Brethon, A.,Chantalat, L.,Christin, O.,Comino, C.,El-Bazbouz, G.,Ghilini, A.L.,Isabet, T.,Lardy, C.,Luzy, A.P.,Mathieu, C.,Mebrouk, K.,Orfila, D.,Pascau, J.,Reverse, K.,Roche, D.,Rodeschini, V.,Hennequin, L.F.
Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne.
J. Med. Chem., 61:4030-4051, 2018

PubMed Abstract: The use of an interleukin β antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1β into active IL-1β, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to a published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases. Reversibility was assessed in an enzymatic dilution assay or by using different substrate concentrations. In addition to classical structure-activity-relationship exploration, topical administration challenges such as phototoxicity, organic and aqueous solubility, chemical stability in solution, and skin metabolic stability are discussed and successfully resolved.

PubMed: 29648825
DOI: 10.1021/acs.jmedchem.8b00067

実験手法

X-RAY DIFFRACTION (1.8 Å)